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Chemoradiotherapy (CRT) is now widely accepted as the primary treatment modality for squamous cell cancer of the anus. While
randomised trials have clearly shown CRT to be more effective than radiotherapy alone, there remains uncertainty over the optimal
integration of chemotherapy and radiation. We describe a series of 50 patients treated by a site specialist gastrointestinal nonsurgical
oncologist with CRT at a single UK centre. Chemotherapy comprised mitomycin C (MMC) (day 1) and 5-fluorouracil (5-FU) (days
1–4, and 29–32), concurrent with 50Gy in 25 fractions radiation, using a two-phase shrinking field technique. A radiation boost was
not planned. At a median follow-up of 48 months, 11 (22%) of the patients have failed locally, of which three have been surgically
salvaged. Nine (18%) have died of anal cancer. These results are comparable with those from large randomised studies, and suggest
that a two-phase shrinking field radiotherapy technique with no boost, concurrent with MMC/5-FU chemotherapy, is an effective
regimen for this disease. The CRT regimen described here provides the basis for the ‘control arm’ of the current UK-randomised
CRT trial in anal cancer (ACT2).
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Chemoradiotherapy (CRT) is now established as the primary
treatment modality for squamous anal cancer, with surgery
reserved for persistent or recurrent disease. The pioneering work
of Norman Nigro first showed in a case report that anal cancer was
responsive to CRT (Nigro et al, 1974). The same institution
subsequently published their experience of 45 patients treated with
CRT using 30Gy radiation combined with mitomycin C (MMC)
and 5-fluorouracil (5-FU). Thirty-eight (84%) patients had
evidence of histopathologically confirmed complete response on
biopsy performed 6 weeks after completion of CRT (Leichman et al,
1985). Of these 38 complete responders, 89% remained disease free
at a median follow-up of 50 months. Further evidence supported
these results; Cummings et al reported their experience of 192
patients treated between 1958 and 1989 in seven small sequential
studies. There were differences in radiotherapy fractionation,
continuous vs split-course treatment and concurrent chemother-
apy schedules (5-FU either alone or in combination with MMC).
Although the numbers treated in each individual protocol were
small, the combination of radiation, 5-FU and MMC appeared to
give the highest rates of local control (Cummings et al, 1991).
Two large randomised trials, conducted by the United Kingdom
Coordinating Committee for Cancer Research (UKCCCR) and the
European Organization for Research and Treatment of Cancer
(EORTC), demonstrated that CRT using concurrent 5-FU and
MMC is superior to radiotherapy alone in the treatment of anal
cancer, using the end points of local failure and colostomy-free
survival (Anonymous, 1996; Bartelink et al, 1997). Furthermore, a
Radiation Therapy and Oncology Group (RTOG) and Eastern
Cooperative Oncology Group (ECOG) trial showed that MMC
combined with 5-FU was superior to 5-FU alone when combined
with radiation for colostomy-free survival (Flam et al, 1996).
These results from phase III randomised trials established the
place of CRT in the treatment of anal cancer, and signalled the
diminishing role of surgical resection in the primary management
of this disease (Northover, 1991). Currently, the combination of
5-FU and MMC is accepted as standard chemotherapy within CRT
for anal cancer, but the radiotherapy component of this
combination treatment varies. The European trials employed an
initial CRT treatment of 45Gy, followed by a 6-week gap, and a
boost with either external beam radiotherapy (15Gy) or
brachytherapy (25Gy). In contrast, the RTOG trial reserved a
boost only for those patients with biopsy-proven residual disease 6
weeks after initial CRT.
We chose to investigate a radiation regimen that treats
macroscopic disease to 50Gy and potential areas of microscopic
disease to 30Gy with a two-phase shrinking field technique using
2Gy per fraction, and no boost. The rationale for omitting the
boost is as follows. Firstly, there is no radiobiological basis for
leaving a 6-week gap between initial CRT and delivery of a boost to
the primary tumour. Indeed, such a gap during radiotherapy may
be detrimental, allowing tumour cell repopulation. Secondly, the
clinical evidence suggests that a boost may not be necessary. The
RTOG trial showed that only 8% of patients had residual disease
requiring a boost following biopsy confirmation 6 weeks after CRT
(Flam et al, 1996), while in the UKCCCR trial, the minority of
patients (approximately 10%) who did not receive their boost as
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lpart of planned treatment, had an outcome similar to those
who did receive a boost (Anonymous, 1996). Although regional
failure is potentially a significant problem in anal cancer, 30Gy
appeared to be adequate for even macroscopic disease in the series
of 45 patients from Nigro’s group, suggesting high intrinsic
sensitivity of this disease to the CRT combination (Nigro et al,
1983). It is therefore reasonable to postulate that a dose of 30Gy
may also be adequate for microscopic disease. In addition, there is
evidence that avoiding wide-field radiotherapy throughout CRT
may significantly reduce long-term toxicity (Jenkins et al, 1995).
Hence, we have chosen to use a two-phase shrinking field
radiotherapy technique, restricting a higher dose (50Gy) to
macroscopic disease only. A simplified, prescriptive radiotherapy
protocol without a boost, as described here, is also likely to lead to
better compliance and improved quality assurance in future phase
III trials.
MATERIALS AND METHODS
Fifty patients with biopsy-proven squamous carcinoma of the
anus were treated between March 1996 and December 1999.
Patients were referred to a single clinical oncologist at the
Leeds Cancer Centre, Cookridge Hospital, Leeds, from 20 surgeons
in 11 surrounding hospitals. All patients were of World
Health Organisation (WHO) performance status 0 or 1, and had
been staged to exclude metastatic disease prior to treatment by
chest X-ray and CT scan of abdomen and pelvis. None of the
patients was HIV positive. Data are reported at a median follow-up
of 48 months (range 29–73 months). Follow-up was performed
jointly between the oncologist and the referring surgeon. Local
failure was defined as biopsy-proven persistent or recurrent
disease more than 3 months following definitive CRT. Pretreat-
ment characteristics are given in Table 1. Tumour site was defined
as exclusively anal canal or margin, or by the location of the
majority of the disease (canal greater than margin, or margin
greater than canal).
Chemotherapy
Concurrent chemotherapy comprised MMC (8–12mgm
 2) on day
1 of radiotherapy, and 5-FU (750–1000mgm
 2) on days 1–4 and
29–32. Lower doses were used when clinically indicated according
to individual patient age and frailty. All patients were considered
fit for two-phase CRT, with creatinine clearance 460mlmin
 1
(Cockroft/Gault estimate (Cockcroft and Gault, 1976) or
51CrEDTA
(Chandler et al, 1969)), white cell count 43.0, neutrophils 41.2
and platelets 4100. Fifteen patients received neoadjuvant chemo-
therapy (five patients one course, 10 patients two courses of
cisplatin 80mgm
 2 day 1; 5-FU 800mgm
 2 days 1–4 q21 days)
prior to definitive CRT, for symptomatic relief of severe local
symptoms.
Radiotherapy
Both phases of treatment were simulated at the same time. Patients
were simulated and treated prone with a full bladder. All
macroscopic primary tumour and involved nodes were considered
for planning purposes as gross target volume (GTV). Node
involvement was defined clinically and, for pelvic nodes,
radiologically; fine-needle aspiration was not employed. The
majority of patients were planned using orthogonal films
throughout; small bowel opacification and rectal contrast were
routinely used. However, a minority of patients required CT
planning for phase II if they were unable to tolerate a rectal
catheter for the insertion of rectal contrast. Macroscopic disease in
the inguinal and femoral lymph node region or on the perianal
skin was marked by wire. Moulded wax block bolus to the perianal
skin was used for both phases of treatment.
Phase I was the same for node-positive and -negative disease,
and comprised large parallel opposed fields to include GTV and
areas of potential microscopic disease including both inguinofe-
moral regions. The superior border was 0–2cm above the bottom
of the SI joints (¼2cm above the superior level of true bony
pelvis). The lateral border was defined to cover both inguinal nodal
regions, passing through the neck of the femora (Figure 1). The
inferior border was 3cm below the inferior extent of the primary
GTV, or the anal margin, whichever was more inferior. Phase I
dose was 30Gy in 15 fractions.
Phase II (node negative). Treatment was planned using
orthogonal films. Treatment fields (three or four field plan) were
designed to treat GTV with a 2–3cm margin in all directions
(Figure 1). For patients with disease confined to the anal margin,
with no canal involvement, a single direct photon field was used to
Phase I − 30 Gy in 15 fractions (parallel opposed fields)
Phase II − 20 Gy in 10 fractions (three-four-field plan)
Figure 1 Radiotherapy treatment planning for a node-negative, anal
canal tumour.
Table 1 Pretreatment characteristics
Characteristic Number %
Age, years
o60 22 44
460 28 56
Median 62
Range 35–85
Sex
Male 18 36
Female 32 64
Tumour stage
T1 2 4
T2 13 26
T3 31 62
T4 4 8
Nodal stage
Node negative 37 76
Node positive 13 24
Tumour site
Canal only 25 50
Canal4margin 12 24
Margin only 7 14
Margin4canal 6 12
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lcover GTV with a 3cm margin. The phase II dose was 20Gy in 10
fractions.
Phase II (node positive). Parallel-opposed fields were used.
Phase II of treatment was 20Gy in 10 fractions, and covered GTV
with a 3cm margin in all directions.
Radiotherapy treatment planning (illustrated by fields for a
node-negative anal canal tumour) is summarised in Figure 1.
In 11 patients, radiotherapy was given as a single phase using
small fields throughout. In two cases this was because of early-
stage disease (T1N0), and in nine patients because patients were
assessed as too frail to tolerate skin toxicity from wide-field
treatment. Although no boost radiotherapy was planned in this
protocol, three patients did receive a further 15Gy in six fractions
of external beam radiotherapy 6 weeks after definitive CRT,
because of the presence of persistent, palpable disease.
All patients were given prophylactic antibiotics (co-trimoxazole
early in the series, then later ciprofloxacin) during CRT.
Statistical methods
Local failure, disease-free survival and overall survival were estimated
according to the Kaplan–Meier method (Kaplan and Meier, 1958).
RESULTS
Local and distant patterns of failure
In all, 47 patients completed CRT to the planned radiotherapy dose
of 50Gy. With a median follow-up of 48 months, the local failure
rate for the whole group is 22% (11 patients). These local failures
comprise 1 of 15 (7%) patients with T1/T2 disease, and 10
of 35 (28%) with T3/T4 disease. When local failure is considered
with respect to nodal status, local failure has occurred in eight
of 38 (21%) patients with node-negative disease, and three
of 12 (25%) with node-positive disease. The three node-positive
patients who relapsed had perianal, perianal and perirectal, and
perineal disease with unilateral inguinal lymphadenopathy,
respectively. All of the eight node-negative patients who relapsed
locally did so with perianal recurrence without significant lymph
node involvement.
Local failure occurred in four patients within 3 months of
completion of CRT, four at 3–6 months, and three at greater than
12 months after completion of CRT. This suggests that the majority
of patients failing locally do so early after treatment; the four
patients who relapsed within 3 months probably never achieved
remission.
Eight patients have relapsed with distant metastases (of whom
seven presented initially with T3/T4 disease) – of these, five have
also failed locally. Sites of distant failure were liver (three patients),
skin (one), perineum (one), bone (one) and mediastinal (one) or
para-aortic lymph nodes (one). Local control and patterns of
recurrence are summarised in Figure 2 and Table 2.
Colostomy
Nine patients have undergone anorectal excision for persistent or
recurrent disease. Eight of these patients originally had T3/4
disease, and one had T2 disease. Three of these patients remain
disease free to date, five have developed distant metastases and/or
uncontrolled locoregional disease, and one has had two further
local surgical excisions and is currently alive with locoregional
disease. Three further colostomies have been performed, one due
to bowel toxicity from treatment, and two in patients with poor
anorectal function at presentation, which did not improve
following CRT. The one patient with severe late radiation
morbidity secondary to small bowel damage required colostomy
and total parenteral nutrition. Radionecrosis has not been seen
following treatment.
Survival
Thirteen patients have died, nine of anal cancer. One patient who
died postoperatively following a colostomy had stopped CRT at
30Gy on the completion of phase I of treatment. One death
occurred from apparently unrelated cardiac causes 20 days after
the completion of CRT (development of an arrhythmia in a patient
who had no cardiac symptoms previously or while on CRT), and a
further patient who developed severe late bowel toxicity following
treatment died 69 months after completion of CRT with no
evidence of disease recurrence. The final death without recurrence
was from an unrelated malignancy (carcinoma of the oral cavity) at
43 months from treatment. Data for disease-free and overall
survival are shown in Figures 3 and 4.
Radiotherapy compliance
Three patients received less than the planned radiotherapy dose of
50Gy. In two patients, treatment was stopped slightly early (at 48
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Figure 2 Actuarial freedom from local failure by (A) all patients and (B)
T stage.
Table 2 Patterns of failure
Failure Number %
Locoregional alone 6 12
Locoregional and distant metastases 5 10
Distant metastases alone 3 6
Deaths from anal cancer 9 18
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land 43.2Gy) because of severe skin reaction, while in one elderly
patient CRT was stopped after phase I (at 30Gy) owing to general
debility with treatment. Hence, 47 patients (94%) completed the
full radiotherapy course. Only six patients (12%) had interruptions
to treatment totalling four or more working days.
Chemotherapy compliance
Modifications in the CRT chemotherapy regimen of MMC day 1
and 5-FU days 1–4 and 29–32 were as follows. Three patients
received no MMC: one because of poor renal function, one because
of development of chest pain (which was felt to be 5FU-related)
during neo-adjuvant chemotherapy – this patient continued with
cisplatin only in weeks 1 and 5 of CRT, and in one patient, the
reason was not recorded. One patient received only 50% of
the planned MMC dose, for unrecorded reasons. Regarding 5FU,
the above-described patient with chest pain during induction
chemotherapy received no concurrent 5-FU. All other patients
received 5-FU at the planned dose during week 1 of CRT, but five
patients were given no further 5-FU in week 5 (two because of low
blood counts, one due to development of angina, one received
cisplatin only in week 5 – reason unrecorded and in one patient all
treatment was stopped after phase I). A further eight patients had
their dose of 5-FU reduced in week 5 (two mucositis, two
diarrhoea, two low blood counts, one severe desquamation and
one unrecorded).
Acute toxicity
The major acute toxicity was, as expected, severe moist skin
desquamation. In two cases, radiotherapy was stopped early
because of this, at 48 and 43.2Gy. One other patient required a 13-
day break in treatment because of skin toxicity, but completed the
full radiotherapy dose. Acute skin toxicity was managed by Alevyn
dressings and analgesia (usually opiates) as required. Otherwise,
grade 3/4 toxicity comprised diarrhoea in seven patients (14%),
neutropenia in four (8%) and thrombocytopenia in six (12%).
There were no toxic deaths from treatment, or episodes of
neutropaenic sepsis.
DISCUSSION
Chemoradiotherapy is now widely accepted as the primary
treatment modality for squamous anal cancer. Large randomised
trials have now shown that CRT is superior to radiotherapy as a
single treatment modality, and that the combination of MMC and
5-FU is effective as the chemotherapy component of CRT.
However, several areas of controversy remain. The optimal
radiation dose, fractionation and target volumes are uncertain,
as are the roles of brachytherapy and temporal gaps in treatment.
The most effective chemotherapy regimens to use during radio-
therapy, and in the adjuvant setting also remain undecided. The
incidence and severity of long-term toxicity of CRT is also
becoming clearer as more mature series are reported (Myerson
et al, 2001).
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Figure 3 Actuarial disease-free survival by (A) all patients and (B)T
stage.
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Figure 4 Actuarial overall survival by (A) all patients and (B) T stage.
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lNigro’s original series used a dose of only 30Gy, delivered using
parallel-opposed fields at 2Gy per day to cover the primary lesion
with margins including the true pelvis and inguinal lymphatics
(Nigro et al, 1983). The UKCCCR trial used 45Gy over 4 or
5 weeks, again using anterior and posterior opposed fields
(Anonymous, 1996). A target volume including the anus and
inguinal lymph nodes was recommended, although the lymph
nodes could be excluded as a unit policy. Six weeks following
treatment, a clinical assessment of response was made, with good
responders (greater than or equal to 50% response) recommended
for boost radiotherapy (20–25Gy iridium 192 implant or a further
16Gy in six fractions EBRT), and poor responders (less than 50%
response) considered for salvage surgery. The EORTC trial also
used 45Gy in 1.8Gy fractions, delivered by a three- or four-field
technique, with wider parallel-opposed fields specified only for
those with established inguinal lymph node metastases (Bartelink
et al, 1997). A boost of 15Gy (for complete responders), or 20Gy
(for partial responders), was given at 6 weeks using photons,
electrons or an iridium 192 implant. This contrasts with the RTOG
trial, which used a complex shrinking field technique to 45Gy in
1.8Gy fractions, with field sizes reduced at 30.6 and 36Gy (Flam
et al, 1996). If the primary tumour was still palpable after 45Gy, a
further 5.4Gy was given in three fractions. Inguinal lymph node
involvement modified the target volume, such that the anterior
field was extended to include both inguinal regions in N1 disease,
with a further anterior electron or photon boost to bring the nodal
dose at 3cm depth to 50.4Gy. A boost of 9Gy to the primary
tumour was reserved only for the 8% of patients with biopsy-
proved residual disease 6 weeks after initial CRT, so that the
majority of patients in this study received 45–50.4Gy. The
decision regarding total radiotherapy dose was determined by
the biopsy result in this trial. Importantly, the complexity of the
radiotherapy guidelines in the study led to protocol deviations in
over 10% of patients.
Hence, radiotherapy protocols within anal cancer trials are of
variable complexity and design, with no standard approach
accepted. The three large randomised trials in this disease used a
variety of radiotherapy planning techniques and doses, incorpor-
ating different lymph node coverage, single or multiple phases of
treatment, and boost radiotherapy delivered with or without
histological confirmation of persistent disease. With such differing
protocols, effective comparison between trials becomes proble-
matic, and quality assurance of specific radiotherapy techniques
difficult, particularly for the more complex planning specifications.
In this series, we used a shrinking field radiotherapy technique
to 50Gy with MMC/5-FU concurrent chemotherapy. Forty-seven
patients (94%) completed the radiotherapy protocol as planned,
with only one patient having to stop treatment significantly early,
at 30Gy because of problems with poor anorectal function present
prior to the start of CRT. Four patients had reduction or omission
of MMC, and 13 (26%) modification of 5FU in week 5 of CRT. This
compliance is comparable with the UKCCCR trial, in which 91% of
patients completed planned radiotherapy in the CRT arm, and 74%
received both courses of chemotherapy as planned.
Grade 3/4 toxicity was acceptable in this study, and there were
no cases of neutropaenic sepsis or toxic deaths. There was one
death within 3 months of treatment, from causes unrelated to the
anal cancer or its treatment. Severe, long-term morbidity has so far
been confined to one case of bowel toxicity requiring colostomy
and total parenteral nutrition; this patient died without evidence of
recurrence of disease 69 months after completion of treatment.
Both these patients did not complete the full course of CRT. The
patient who died within 3 months stopped treatment at 30Gy
because of general frailty, while the case with long-term bowel
toxicity was stopped at 48Gy due to severe skin toxicity. Since only
three patients did not receive the full radiotherapy dose of 50Gy, it
is not possible to draw conclusions about the completion of
planned radiotherapy and its effect on outcome or toxicity. The
third patient, whose treatment was stopped at 43.2Gy as a result of
skin toxicity, remains disease free 55 months from completion of
treatment. Similarly, the number and variety of chemotherapy
modifications in a series of this size provides no clear guidance on
any correlation between completion of the chemotherapy compo-
nent of treatment, and outcome. There have been no cases of
radionecrosis, consistent with other reports of a low prevalence of
this complication following CRT (Dzik-Jurasz et al, 2001).
However, we have not prospectively collected detailed quality-of-
life information or other potential side effects of treatment, such as
sexual dysfunction, which can be significant (Allal et al, 1999).
The rates of local failure in this study (22%) compare favourably
with those seen in the 5-FU/MMC CRT arms of the large
randomised trials (39% UKCCCR; 34% EORTC; 16% RTOG).
Median follow-up is presently 48 months, and since most relapses
in anal cancer occur within the first 2 years, significant worsening
of these results is not anticipated. Indeed, of the 11 local failures to
date in this series, eight occurred within just 6 months of
completing CRT. There have been no locoregional failures within
the 30Gy treatment volume without failure either locally in the
50Gy volume and/or disseminated disease. This is consistent with
the hypothesis that 30Gy is adequate for microscopic disease,
which is further supported by a recent series in which 30Gy
seemed to be an effective dose in patients with anal cancer treated
by excisional biopsy followed by CRT (Hu et al, 1999). However,
there is evidence that 30Gy is inadequate for control of
macroscopic disease (Myerson et al, 1995). In this retrospective
series, the local control rate for T2/3 patients treated to 30Gy was
63%, compared to 77% for a dose of 40–50Gy.
Since tumours with more advanced T stage and/or node
involvement carry a poor prognosis, the question arises whether
selected patients should be treated with escalating doses of
radiation, and how boost treatments should be delivered (external
beam or brachytherapy). Recent evidence in oesophageal cancer
suggests that increasing the radiotherapy component of CRT may
carry significant morbidity without benefit (Minsky et al, 2002).
Consequently, in oesophageal cancer the recommended radiation
dose from this series remains at 50.4Gy. There is little evidence to
support the use of a boost in anal cancer, since less than 10% of
patients have persistent disease after a dose of 45–50.4Gy (Flam
et al, 1996), and the efficacy of any boost remains unproven
(Anonymous, 1996). Moreover, recent evidence suggests that
increasing the duration of any gap in split-course CRT for anal
cancer has a negative impact on locoregional control (Weber et al,
2001). Therefore, the use of continuous external beam radio-
therapy with no breaks in treatment, as described here, is a
rational protocol design of CRT for anal cancer.
It is however important to establish whether cisplatin is superior
to MMC when combined with 5-FU and radiation, and whether
there is any benefit from the addition of two cycles of cisplatin/5-
FU maintenance chemotherapy after completion of CRT. These
questions are being addressed in a 2 2 factorial design in the
current UK ACT2 trial.
In summary, this series shows that a shrinking field radiation
technique with no boost is an acceptable component of radical
CRT for anal cancer. Toxicity, colostomy, local failure and survival
rates are consistent with previous data. The use of a clearly defined
radiotherapy protocol is likely to improve compliance and simplify
quality assurance in future CRT trials, in anal and other cancers.
The technique described here is providing the basis for the
radiotherapy technique in the ACT II trial.
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